1. 17P Using ex vivo organ culture technology to evaluate a T cell bispecific (TCB) CEACAM5 therapy. (December 2022) Authors: Zundelevich, A.; Ibrahim, B.; Turovsky, L.; Aharon, S.; Bar, V.; Salpeter, S.; Neev, G.; Straussman, R.; Silva, I.; Li, S.; Herter, S.; Bacac, M.; Sadok, S.; Gjorevski, N. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CD20‐TCB (RG6026), A NOVEL "2:1" FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA. (12th June 2019) Authors: Dickinson, M.J.; Morschhauser, F.; Iacoboni, G.; Carlo‐Stella, C.; Offner, F.C.; Sureda, A.; Salles, G.; Martinez, J.; Crump, M.; Thomas, D.N.; Morcos, P.N.; Ferlini, C.; Broeske, A.; Bacac, M.; Dimier, N.J.; Umaña, P.; Moore, T.; Weisser, M.; Hutchings, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 92 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S141: ELICITING ANTI-TUMOR T CELL ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH BISPECIFIC ANTIBODY-BASED COMBINATION THERAPY. (23rd June 2022) Authors: Papazoglou, D.; Ysebaert, L.; Ioannou, N.; Apollonio, B.; Patten, P.; Herter, S.; Bacac, M.; Deutsch, A.; Klein, C.; Vardi, A.; Quillet-Mary, A.; Ramsay, A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗